Vol 3 No 3: 7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009
7th Meeting New Insights in Hematology Venice, Italy, 26-29 April 2009

Articles

G Saglio, G Parvis, M Bosa
Molecular targeted therapies for indolent lymphomas: where are we?
PDF
RT Hoppe
The indolent extranodal lymphomas: What is the role of radiation therapy?
PDF
N Giuliani, V Rizzoli
Alterations of microenvironment in multiple myeloma patients: interactions between myeloma cells and osteoprogenitor cells
PDF
A Palumbo, M Genuardi, S Bringhen
New treatment options for elderly myeloma patients: the Italian experience
PDF
M Cavo, E Zamagni, P Tacchetti, A Brioli, C Pallotti, L Pantani, M Ceccolini, A Petrucci, N Testoni, C Terragna, G Marzocchi, S Durante, P Tosi, M Baccarani
The road to cure in multiple myeloma: incorporation of novel agents into autologous stem cell transplantation
PDF
A Maiolino, V Tietsche de Moraes Hungria, M Nucci, C De Souza
The role of thalidomide as maintenance after autologous stem-cell transplantation in multiple myeloma
PDF
M Attal
The role of maintenance treatment in myeloma
PDF
AH Goldstone
Have maintenance rituximab and RIC allograft blown away the need for autografts in follicular lymphoma?
PDF
AM Carella, E Todisco, A Congiu, L Castagna, G Pica, G Beltrami, S Nati, R Vimercati, E Rossi, M Spriano, G Catania, A Santoro
Reduced-intensity conditioning for allograft after cytoreductive autograft in relapsed/ resistant Hodgkin’s lymphoma
PDF
P Corradini, A Dodero, L Farina, R Fanin, F Patriarca, R Miceli, P Matteucci, R Scimè, F Narni, S Dalto, C Carniti, A Bacigalupo, F Bonifazi, A Olivieri, C Tarella
Long-term results of reduced-intensity conditioning followed by allogeneic transplantation in relapsed lymphomas
PDF
BKL Duarte, AC Vigorito, FJP Aranha, R Baldissera, ECM Miranda, IL Lorand-Metze, KB Pagnano, CA De Souza
Brazilian experience using high dose sequential followed by autologous hematopoietic stem cell transplantation for malignant lymphomas
PDF
PP Piccaluga, F Bacci, E Sabattini, M Rossi, A Gazzola, MR Sapienza, C Mannu, S Righi, C Bertuzzi, C Agostinelli, MT Sista, C Laterza, S Parisi, SA Pileri
Large cell non Hodgkin’s lymphoma: what is new in the WHO classification?
PDF
B Coiffier
High-dose CHOP in the rituximab era: still a place?
PDF
M Pfreundschuh
Radiotherapy in the rituximab era: still a place?
PDF
SJ Horning
S.J. Horning Biomarkers in diffuse large B-cell lymphoma
PDF
U Vitolo, A Chiappella, B Botto
High dose chemotherapy and autologous transplantation in anti-CD20 antibodies era: still a place?
PDF
L Catani
Recent advances in the pathology of idiopathic thrombocytopenic purpura
PDF
F Zaja, R Fanin
Idiopathic thrombocytopenic purpura in adults: the treatment paradigm
PDF
A Cuker, EY Chiang, DB Cines
Thrombopoietin receptor agonists in the treatment of chronic immune thrombocytopenic purpura
PDF
F Caligaris-Cappio, C Scielzo, S Bertilaccio, M Muzio, P Ghia
Are we getting closer to understanding the pathogenesis of chronic lymphocytic leukemia?
PDF
M Ferrarini
The continuing search for the cell of origin of chronic lymphocytic leukemia
PDF
A Cuneo, F Cavazzini, M Ciccone, M Dabusti, F Cibien, G Daghia, O Sofritti, GM Viglione, GM Rigolin
Molecular cytogenetic lesions in chronic lymphocytic leukemia
PDF
R Foà, A Guarini, I Del Giudice, S Tavolaro, S Chiaretti
What is gene profiling contributing to the characterization of chronic lymphocytic leukemia
PDF
V Liso, R Rizzi
The impact of diagnosis on the therapeutic management of chronic lymphocytic leukemia
PDF
MJ Keating
How close are we to curing chronic lymphocytic leukemia?
PDF
M Gobbi
Cyclophosphamide in chronic lymphocytic leukemia first line: final results of Chronic Lymphocytic Leukemia 8 Study
PDF
A Ferrajoli, SM O’Brien, SM O’Brien, S Faderl1, S Faderl1, WG Wierda, WG Wierda, JM Reuben, JM Reuben, MJ Keating, MJ Keating
Lenalidomide: an emerging option in chronic lymphocytic leukemia
PDF
M Montillo
Ofatumumab: a second generation anti-CD20 monoclonal antibody in chronic lymphocytic leukemia
PDF
G Finazzi, T Barbui
Hydroxyurea: the comparator in studies with new anti-JAK2 inhibitors
PDF
GP Canellos, W Rosenberg
New biologic and therapeutic insights in Hodgkin’s lymphoma
PDF
DJ Straus
Treatment approaches in early stage Hodgkin’s lymphoma
PDF
V Diehl
Advanced Hodgkin’s lymphoma: doxorubicin, bleomycin, vinblastine, dacarbazine and beyond
PDF
S Luminari, M Federico, A Montanini, E Iannitto, G Polimeno, PG Gobbi
Bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone outside German Hodgkin Study Group: the Italian experience
PDF
A Santoro, A Anastasia, R Mazza
Treatment of refractory Hodgkin’s lymphoma: a puzzle to merge
PDF
F Facchetti, M Ungari, D Marocolo, S Lonardi, W Vermi
Blastic plasmacytoid dendritic cell neoplasm
PDF